tiprankstipranks
Trending News
More News >

SSY Group Secures Approval for New Injectable Drugs

Story Highlights
SSY Group Secures Approval for New Injectable Drugs

Confident Investing Starts Here:

An update from SSY Group ( (HK:2005) ) is now available.

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new injectable drugs: Nicardipine Hydrochloride Injection and Sodium Bicarbonate Injection. These approvals mark significant progress in the company’s product development, enhancing its portfolio in emergency and metabolic treatment solutions, potentially strengthening its market position and offering new opportunities for growth.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company specializes in creating pharmaceutical products, particularly in the form of injections, aimed at treating various medical conditions.

YTD Price Performance: -6.47%

Technical Sentiment Signal: Buy

Current Market Cap: $1.2B

For an in-depth examination of 2005 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App